AbbVie Inc.
For the period ended Dec 31, 2025. Filed Feb 20, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 20, 2026
ABBV$293.89+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Equity (Deficit)
| years ended December 31 (in millions) | Common shares outstanding | Common stock | Treasury stock | Additional paid-in capital | Retained earnings (accumulated deficit) | Accumulated other comprehensive loss | Noncontrolling interest | Total |
|---|---|---|---|---|---|---|---|---|
| Balance at December 31, 2022 | 1,769 | $18 | $(4,594) | $19,245 | $4,784 | $(2,199) | $33 | $17,287 |
| Net earnings attributable to AbbVie Inc. | — | — | — | — | 4,863 | — | — | 4,863 |
| Other comprehensive loss, net of tax | — | — | — | — | — | (106) | — | (106) |
| Dividends declared | — | — | — | — | (10,647) | — | — | (10,647) |
| Purchases of treasury stock | (12) | — | (1,978) | — | — | — | — | (1,978) |
| Stock-based compensation plans and other | 9 | — | 39 | 935 | — | — | — | 974 |
| Change in noncontrolling interest | — | — | — | — | — | — | 4 | 4 |
| Balance at December 31, 2023 | 1,766 | 18 | (6,533) | 20,180 | (1,000) | (2,305) | 37 | 10,397 |
| Net earnings attributable to AbbVie Inc. | — | — | — | — | 4,278 | — | — | 4,278 |
| Other comprehensive income, net of tax | — | — | — | — | — | 380 | — | 380 |
| Dividends declared | — | — | — | — | (11,178) | — | — | (11,178) |
| Purchases of treasury stock | (9) | — | (1,703) | — | — | — | — | (1,703) |
| Stock-based compensation plans and other | 8 | — | 35 | 1,153 | — | — | — | 1,188 |
| Change in noncontrolling interest | — | — | — | — | — | — | 2 | 2 |
| Balance at December 31, 2024 | 1,765 | 18 | (8,201) | 21,333 | (7,900) | (1,925) | 39 | 3,364 |
| Net earnings attributable to AbbVie Inc. | — | — | — | — | 4,226 | — | — | 4,226 |
| Other comprehensive income, net of tax | — | — | — | — | — | 781 | — | 781 |
| Dividends declared | — | — | — | — | (11,819) | — | — | (11,819) |
| Purchases of treasury stock | (5) | — | (980) | — | — | — | — | (980) |
| Stock-based compensation plans and other | 8 | — | 35 | 1,162 | — | — | — | 1,197 |
| Change in noncontrolling interest | — | — | — | — | — | — | 3 | 3 |
| Balance at December 31, 2025 | 1,768 | $18 | $(9,146) | $22,495 | $(15,493) | $(1,144) | $42 | $(3,228) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.